An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma
Current Protocols · 2026-11 · 6 (11)
DOI: 10.1002/cpz1.70503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Protocols, online erschienen am 30.10.2026. Verfasst von Julian Hübner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Cellular Immunotherapy, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, Adoptive, Brain Neoplasms, Receptors, Chimeric Antigen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is the most lethal primary brain tumor in adults, and despite intensive research efforts, effective therapeutic breakthroughs remain elusive. Consequently, the standard of care has remained largely unchanged for nearly 30 years, underscoring the need for robust preclinical models to evaluate experimental therapies. One particularly promising approach is chimeric antigen receptor (CAR) T cell therapy, which has demonstrated remarkable success in several hematologic malignancies but has not yet achieved comparable efficacy in solid tumors. This article describes the generation of orthotopic GBM xenografts in NSG mice, including anesthesia, surgical procedures, and postoperative care, followed by locoregional delivery of human CAR T cells into the lateral ventricle and subsequent assessment of therapeutic efficacy. Together, these protocols provide a reliable platform for evaluating GBM‐directed CAR T cell therapies in both basic and translational research. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Intracranial tumor implantation Basic Protocol 2 : Intraventricular CAR T cell administration Support Protocol 1 : Bioluminescence imaging of xenografts Support Protocol 2 : Endpoint analysis of residual tumor burden by flow cytometry
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chair of Cellular Immunotherapy, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany.
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany.
- Department of Medicine II, University Hospital Würzburg, Würzburg, Germany.
Zitieren
APA
Hübner, J., McFleder, R., Ip, C. W., Alb, M., Einsele, H., Hudecek, M., & Nerreter, T. (2026). An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma. Current Protocols, 6(11). https://doi.org/10.1002/cpz1.70503
Vancouver
Hübner J, McFleder R, Ip CW, Alb M, Einsele H, Hudecek M, et al. An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma. Current Protocols. 2026;6(11). doi:10.1002/cpz1.70503
BibTeX
@article{Hbner2026,
author = {Hübner, Julian and McFleder, Rhonda and Ip, Chi Wang and Alb, Miriam and Einsele, Hermann and Hudecek, Michael and Nerreter, Thomas},
title = {An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma},
journal = {Current Protocols},
year = {2026},
volume = {6},
number = {11},
doi = {10.1002/cpz1.70503}
}
EUVIMED